APA

Reid T., Oronsky B., Scicinski J., Scribner C. L., Knox S. J., Ning S., Peehl D. M., Korn R., Stirn M., Carter C. A., Oronsky A., Taylor M. J., Fitch W. L., Cabrales P., Kim M. M., Burris H. A., Lao C. D., Abrouk N. E. D., Fanger G. R. & Infante J. R. (20151214). Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study. : The Lancet. Oncology.

Chicago

Reid Tony, Oronsky Bryan, Scicinski Jan, Scribner Curt L, Knox Susan J, Ning Shoucheng, Peehl Donna M, Korn Ron, Stirn Meaghan, Carter Corey A, Oronsky Arnold, Taylor Michael J, Fitch William L, Cabrales Pedro, Kim Michelle M, Burris Howard A, Lao Christopher D, Abrouk Nacer E D, Fanger Gary R and Infante Jeffrey R. 20151214. Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study. : The Lancet. Oncology.

Harvard

Reid T., Oronsky B., Scicinski J., Scribner C. L., Knox S. J., Ning S., Peehl D. M., Korn R., Stirn M., Carter C. A., Oronsky A., Taylor M. J., Fitch W. L., Cabrales P., Kim M. M., Burris H. A., Lao C. D., Abrouk N. E. D., Fanger G. R. and Infante J. R. (20151214). Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study. : The Lancet. Oncology.

MLA

Reid Tony, Oronsky Bryan, Scicinski Jan, Scribner Curt L, Knox Susan J, Ning Shoucheng, Peehl Donna M, Korn Ron, Stirn Meaghan, Carter Corey A, Oronsky Arnold, Taylor Michael J, Fitch William L, Cabrales Pedro, Kim Michelle M, Burris Howard A, Lao Christopher D, Abrouk Nacer E D, Fanger Gary R and Infante Jeffrey R. Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study. : The Lancet. Oncology. 20151214.